The cardioprotective protein apolipoprotein a1 promotes potent anti-tumorigenic effects

Journal of Biological Chemistry

Volumn 288, Issue 29, 2013, Pages 21237-21252

  Zamanian Daryoush, Maryam ^a,b   Lindner, Daniel ^c   Tallant, Thomas C ^a,b   Wang, Zeneng ^a,b   Buffa, Jennifer ^a,b   Klipfell, Elizabeth ^a,b   Parker, Yvonne ^c   Hatala, Denise ^d   Parsons Wingerter, Patricia ^e   Rayman, Pat ^a   Yusufishaq, Mohamed Sharif S ^a   Fisher, Edward A ^f   Smith, Jonathan D ^a   Finke, Jim ^a   DiDonato, Joseph A ^a,b   Hazen, Stanley L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Center for Cardiovascular Diagnostics and Prevention   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d Imaging Core ^*  (United States)

^e NASA GLENN RESEARCH CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNE RESPONSE; ANTI-INFLAMMATORIES; APOLIPOPROTEIN A-1; IMMUNE CELLS; IMMUNOMODULATORY; MULTIPLE LEVELS; TUMOR BIOLOGY; TUMOR SUPPRESSION;

BIOCHEMISTRY; BIOLOGY;

TUMORS;

APOLIPOPROTEIN A1; GELATINASE B; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; TUMOR REJECTION; UBIQUITINATION;

ADAPTIVE IMMUNITY; APOLIPOPROTEIN A1 THERAPY; CANCER; CANCER BIOLOGY; CANCER THERAPY; HIGH DENSITY LIPOPROTEIN (HDL); INNATE IMMUNITY; MATRIX METALLOPROTEINASE 9 (MMP-9); MELANOMA; TUMOR-SUPPRESSIVE INFILTRATING LEUKOCYTES;

ANIMALS; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CARCINOGENESIS; CARDIOTONIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY; IMMUNOCOMPETENCE; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84880555169     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.468967     Document Type: Article

References (65)

1. Linos, E., Swetter, S. M., Cockburn, M. G., Colditz, G. A., and Clarke, C. A. (2009) Increasing burden of melanoma in the United States. J. Invest. Dermatol. 129,1666-1674
2. Godar, D. E. (2011) Worldwide increasing incidences of cutaneous malignant melanoma. J. Skin Cancer 2011:858425
3. Navarini-Meury, A. A., and Conrad, C. (2009) Melanoma and innate immunity-active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin. Cancer Biol. 19, 84-91
4. Libby, P., Ridker, P. M., and Hansson, G. K. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325
5. Weber, C., and Noels, H. (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17,1410-1422
6. Mantovani, A. (2010) Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10, 369-373
7. Ben-Neriah, Y., and Karin, M. (2011) Inflammation meets cancer, with NF-kB as the matchmaker. Nat. Immunol. 12, 715-723
8. Colotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081
9. Rye, K. A., Bursill, C. A., Lambert, G., Tabet, F., and Barter, P. J. (2009) The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50, S195-S200
10. Khera, A. V., Cuchel, M., de laLlera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., Mohler, E. R., Rothblat, G. H., and Rader, D. J. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J.Med. 364,127-135
11. Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Bar-balic, M., Jensen, M. K., Hindy, G., Holm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., Pirruccello, J. P., Saleheen, D., Chen, L., Stewart, A. F., Schillert, A., Thorsteinsdottir, U., Thorgeirsson, G., Anand, S., Engert, J. C., Morgan, T., Spertus, J., Stoll, M., Berger, K., Martinelli, N., Girelli, D., McKeown, P. P., Patterson, C. C., Epstein, S. E., Devaney, J., Burnett, M.-S., Mooser, V., Ripatti, S., Surakka, I., Nieminen, M. S., Sinisalo, J., Lokki, M.-L., Havulinna, A., de Faire, U., Gigante, B., Ingelsson, E., Zeller, T., Wild, P., de Bakker, P. I., Klungel, O. H., Maitland-van der Zee, A.-H., Peters, B. J., de Boer, A., Grobbee, D. E., Kamphuisen, P. W., Deneer, V. H., Elbers, C. C., Onland-Moret, N. C., Hofker, M. H., Wijmenga, C., Verschuren, W. M., Boer, J. M., van der Schouw, Y. T., Rasheed, A., Frossard, P., Demissie, S., Willer, C., Do, R., Ordovas, J. M., Abecasis, G. R., Boehnke, M., Mohlke, K. L., Daly, M. J., Guiducci, C., Burtt, N. P., Surti, A., Gonzalez, E., Purcell, S., Gabriel, S., Marrugat, J., Peden, J., Erdmann, J., Diemert, P., Willenborg, C., König, R., Fischer, M., Hengstenberg, C., Ziegler, A., Buysschaert, I., Lambrechts, D., Van de Werf, F., Fox, K. A., El Mokhtari, N. E., Rubin, D., Schrezenmeir, J., Schreiber, S., Schäfer, A., Danesh, J., Blankenberg, S., Roberts, R., McPherson, R., Watkins, H., Hall, A. S., Overvad, K., Rimm, E., Boerwinkle, E., Tybjaerg-Hansen, A., Cupples, L. A., Reilly, M. P., Me-lander, O., Mannucci, P. M., Ardissino, D., Siscovick, D., Elosua, R., Ste-fansson, K., O'Donnell, C. J., Salomaa, V., Rader, D. J., Peltonen, L., Schwartz, S.M., Altshuler, D., Kathiresan, S., andPerola, M. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572-580
12. Camont, L., Chapman, M. J., andKontush, A. (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol.Med. 17, 594-603
13. Gordon, S. M., Hofmann, S., Askew, D. S., and Davidson, W. S. (2011) High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol. Metab. 22, 9-15
14. Cockerill, G. W., Rye, K. A., Gamble, J. R., Vadas, M. A., and Barter, P. J. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987-1994
15. Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D. P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., Moguilevsky, N., Dieu, M., Kane, J. P., De Baetselier, P., Brasseur, R., and Pays, E. (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422, 83-87
16. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmitt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., and Hazen, S. L. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299,1265-1276
17. de Souza, J. A., Vindis, C., Negre-Salvayre, A., Rye, K. A., Couturier, M., Therond, P., Chantepie, S., Salvayre, R., Chapman, M. J., and Kontush, A. (2010) Small, dense HDL 3 particles attenuate apoptosis in endo-thelial cells: Pivotal role of apolipoprotein A-I. J. Cell. Mol. Med. 14, 608-620
18. Fuhrman, B., Gantman, A., andAviram,M. (2010) Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 211, 61-68
19. Srinivas, R. V., Venkatachalapathi, Y. V., Rui, Z., Owens, R. J., Gupta, K. B., Srinivas, S. K., Anantharamaiah, G. M., Segrest, J. P., and Compans, R. W. (1991) Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J. Cell. Biochem. 45, 224-237
20. Singh, I. P., Chopra, A. K., Coppenhaver, D. H., Ananatharamaiah, G. M., and Baron, S. (1999) Lipoproteins account for part of the broad nonspecific antiviral activity of human serum. Antiviral Res. 42, 211-218
21. Tada, N., Sakamoto, T., Kagami, A., Mochizuki, K., and Kurosaka, K. (1993) Antimicrobial activity of lipoprotein particles containing apolipoprotein Al. Mol. Cell. Biochem. 119, 171-178
22. Wilhelm, A. J., Zabalawi, M., Owen, J. S., Shah, D., Grayson, J. M., Major, A. S., Bhat, S., Gibbs, D. P., Jr., Thomas, M. J., and Sorci-Thomas, M. G. (2010) Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J. Biol. Chem. 285, 36158-36169
23. Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A., and Rubin, A. L. (1993) In vivo protection against endotoxin by plasma high density lipo-protein. Proc. Natl. Acad. Sci. U.S.A. 90,12040-12044
24. Grunfeld, C., Marshall, M., Shigenaga, J. K., Moser, A. H., Tobias, P., and Feingold, K. R. (1999) Lipoproteins inhibit macrophage activation by lipo-teichoic acid. J. Lipid Res. 40, 245-252
25. Degoma, E. M., and Rader, D. J. (2011) Novel HDL-directed pharmaco-therapeutic strategies. Nat. Rev. Cardiol. 8, 266-277
26. Yang, S., Damiano, M. G., Zhang, H., Tripathy, S., Luthi, A. J., Rink, J. S., Ugolkov, A. V., Singh, A. T., Dave, S. S., Gordon, L. I., and Thaxton, C. S. (2013) Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110, 2511-2516
27. Shahzad, M. M., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E. M., Lee, J. W., Stone, R. L., Pecot, C. V., Thanap-prapasr, D., Roh, J. W., Gaur, P., Nair, M. P., Park, Y. Y., Sabnis, N., Deavers, M. T., Lee, J. S., Ellis, L. M., Lopez-Berestein, G., McConathy, W. J., Prokai, L., Lacko, A. G., and Sood, A. K. (2011) Targeted delivery of small interfering RNA using reconstituted high-densitylipoprotein nanoparticles. Neplasia 13, 309-319
28. Gao, F., Vasquez, S. X., Su, F., Roberts, S., Shah, N., Grijalva, V., Imaizumi, S., Chattopadhyay, A., Ganapathy, E., Meriwether, D., Johnston, B., Anan-tharamaiah, G. M., Navab, M., Fogelman, A. M., Reddy, S. T., and Farias-Eisner, R. (2011) L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr. Biol. 3 479-489
29. Su, F., Kozak, K. R., Imaizumi, S., Gao, F., Amneus, M. W., Grijalva, V., Ng, C., Wagner, A., Hough, G., Farias-Eisner, G., Anantharamaiah, G. M., Van Lenten, B. J., Navab, M., Fogelman, A. M., Reddy, S. T., and Farias-Eisner, R. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 107,19997-20002
30. Osborne, J. C., Jr. (1986) Delipidation of plasma lipoproteins. Methods Enzymol. 128, 213-222
31. Weisweiler, P. (1987) Isolation and quantitation of apolipoproteins A-I and A-II from human high-density lipoproteins by fast-protein liquid chromatography. Clin. Chim. Acta 169, 249-254
32. Matz, C. E., and Jonas, A. (1982) Micellar complexes of human apolipo-protein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J.Biol. Chem. 257, 4535-4540
33. Murph, M., Tanaka, T., Pang, J., Felix, E., Liu, S., Trost, R., Godwin, A. K., Newman, R., and Mills, G. (2007) Liquid chromatographymass spectrom-etry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 433,1-25
34. Rubin, E. M., Ishida, B. Y., Clift, S. M., and Krauss, R. M. (1991) Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. U.S.A. 88, 434-438
35. Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H. I., Celis, E., Lennox, B., Knight, S. C., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., Antonia, S., Fishman, M., Ferris, R. L., Kagan, V. E., and Gabrilovich, D. I. (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880-886
36. Kusmartsev, S., and Gabrilovich, D. I. (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Im-munother. 55, 237-245
37. Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., Greiner, D. L., and Hand-gretinger, R. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R7 null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-648
38. Gabrilovich, D. I., and Nagaraj, S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174
39. Condamine, T., and Gabrilovich, D. I. (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19-25
40. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421
41. West, X. Z., Malinin, N. L., Merkulova, A. A., Tischenko, M., Kerr, B. A., Borden, E. C., Podrez, E. A., Salomon, R. G., and Byzova, T. V. (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976
42. Kim, S., and Karin, M. (2011) Role of TLR2-dependent inflammation in metastatic progression. Ann. N. Y. Acad. Sci. 1217,191-206
43. Hofmann, U. B., Houben, R., Brocker, E. B., and Becker, J. C. (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87, 307-314
44. McKenzie, J. A., and Grossman, D. (2012) Role of the apoptotic and mi-totic regulator survivin in melanoma. Anticancer Res. 32, 397-404
45. Piras, F., Murtas, D., Minerba, L., Ugalde, J., Floris, C., Maxia, C., Colombari, R., Perra, M. T., and Sirigu, P. (2007) Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 50, 835-842
46. Yvan-Charvet, L., Pagler, T., Gautier, E. L., Avagyan, S., Siry, R. L., Han, S., Welch, C. L., Wang, N., Randolph, G. J., Snoeck, H. W., and Tall, A. R. (2010) ATP-binding cassette transporters and HDL suppress hematopoi-etic stem cell proliferation. Science 328,1689-1693
47. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883-899
48. Colombo, M. P., and Trinchieri, G. (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168
49. Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., and Hamilton, T. A. (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J.Immunol. 161, 927-932
50. Bauvois, B. (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 1825, 29-36
51. Murphy, A. J., Woollard, K. J., Hoang, A., Mukhamedova, N., Stirzaker, R. A., McCormick, S. P., Remaley, A. T., Sviridov, D., and Chin-Dusting, J. (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071-2077
52. Kim, K. D., Lim, H. Y., Lee, H. G., Yoon, D. Y., Choe, Y. K., Choi, I., Paik, S. G., Kim, Y. S., Yang, Y., and Lim, J. S. (2005) Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem. Biophys. Res. Commun. 338, 1126-1136
53. Wang, S. H., Yuan, S. G., Peng, D. Q., and Zhao, S. P. (2012) HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis 225, 105-114
54. + myeloid cells. Nat. Biotechnol. 25, 911-920
55. Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., and Yu, H. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118, 3367-3377
56. Lamagna, C., Aurrand-Lions, M., and Imhof, B. A. (2006) Dual role of macrophages in tumor growth and angiogenesis. J. Leukocyte Biol. 80, 705-713
57. Pages, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautes-Fridman, C., and Fridman, W. H. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29,1093-1102
58. Clemente, C. G., Mihm, M. C., Jr., Bufalino, R., Zurrida, S., Collini, P., and Cascinelli, N. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303-1310
59. Jafri, H., Alsheikh-Ali, A. A., and Karas, R. H. (2010) Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J.Am. Coll. Cardiol. 55, 2846-2854
60. Chen, W., Lu, F., Liu, S. J., DU, J. B., Wang, J. M., Qian, Y., Shen, C., Jin, G. F., Hu, Z. B., and Shen, H. B. (2012) Cancer risk and key components of metabolic syndrome: a population-based prospective cohort study in Chinese. Chin. Med. J. 125, 481-485
61. Sarov-Blat, L., Kiss, R. S., Haidar, B., Kavaslar, N., Jaye, M., Bertiaux, M., Steplewski, K., Hurle, M. R., Sprecher, D., McPherson, R., and Marcel, Y. L. (2007) Predominance of a proinflammatory phenotype in monocyte-de-rived macrophages from subjects with low plasma HDL cholesterol. Arte-rioscler. Thromb. Vasc. Biol. 27,1115-1122
62. Murphy, A. J., Woollard, K. J., Suhartoyo, A., Stirzaker, R. A., Shaw, J., Sviridov, D., and Chin-Dusting, J. P. (2011) Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1333-1341
63. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., Halpern, S., Crowe, T., Blankenship, J. C., and Kerensky, R. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300
64. Tardif, J. C., Grégoire, J., L'Allier, P. L., Ibrahim, R., Lespérance, J., Hei-nonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M. A., Guertin, M. C., Rodés-Cabau, J., and Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675-1682
65. Sacks, F. M., Rudel, L. L., Conner, A., Akeefe, H., Kostner, G., Baki, T., Rothblat, G., de la Llera-Moya, M., Asztalos, B., Perlman, T., Zheng, C., Alaupovic, P., Maltais, J. A., and Brewer, H. B. (2009) Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J. Lipid Res. 50, 894-907